Belantamab mafodotin (BelaMaf), a humanized IgG1 anti-BCMA monoclonal antibody conjugated to the microtubule inhibitory drug monomethyl auristatin F (MMAF) (Table 1), was the first and, so far, only ADC to receive regulatory approval for myeloma from the Food and Drug Administration. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.